See more : PunaMusta Media Oyj (PUMU.HE) Income Statement Analysis – Financial Results
Complete financial analysis of Bone Therapeutics SA (BOTHE.BR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bone Therapeutics SA, a leading company in the Biotechnology industry within the Healthcare sector.
- Ever Supreme Bio Technology Co., Ltd (6712.TWO) Income Statement Analysis – Financial Results
- Nedbank Group Limited (NDBKY) Income Statement Analysis – Financial Results
- Dyna-Mac Holdings Ltd. (NO4.SI) Income Statement Analysis – Financial Results
- BioMark Diagnostics Inc. (BUX.CN) Income Statement Analysis – Financial Results
- Nurosene Health Inc. (MEND.CN) Income Statement Analysis – Financial Results
Bone Therapeutics SA (BOTHE.BR)
About Bone Therapeutics SA
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.00M | 1.00M | 0.00 | 1.00M | 41.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.00M | 1.00M | 0.00 | 1.00M | 41.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.68M | 15.42M | 11.19M | 12.88M | 13.12M | 13.65M | 12.91M | 7.96M | 6.82M | 6.37M |
| General & Administrative | 1.77M | 1.81M | 1.55M | 1.72M | 1.51M | 1.37M | 1.23M | 657.00K | 339.00K | 348.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.77M | 1.81M | 1.55M | 1.72M | 1.51M | 1.37M | 1.23M | 657.00K | 339.00K | 348.00K |
| Other Expenses | -426.00K | -1.21M | -1.56M | -2.14M | -2.30M | -2.22M | -1.91M | -2.99M | -3.11M | -3.06M |
| Operating Expenses | 13.03M | 16.02M | 11.17M | 12.47M | 12.34M | 12.80M | 12.22M | 5.63M | 4.04M | 3.66M |
| Cost & Expenses | 13.03M | 16.02M | 11.17M | 12.47M | 12.34M | 12.80M | 12.22M | 5.63M | 4.04M | 3.66M |
| Interest Income | 358.00K | 23.00K | 26.00K | 66.00K | 198.00K | 173.00K | 193.00K | 124.00K | 150.00K | 172.00K |
| Interest Expense | 845.00K | 678.00K | 398.00K | 301.00K | 423.00K | 388.00K | 284.00K | 254.00K | 176.00K | 0.00 |
| Depreciation & Amortization | 186.00K | 601.00K | 753.00K | 580.00K | 524.00K | 537.00K | 394.00K | 371.00K | 407.00K | 402.00K |
| EBITDA | -11.81M | -10.58M | -9.27M | -13.21M | -11.63M | -12.12M | -13.41M | -5.11M | -3.50M | -3.29M |
| EBITDA Ratio | -1,180.50% | -1,058.30% | 0.00% | -1,320.60% | -28,358.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.99M | -11.18M | -10.03M | -13.79M | -12.15M | -12.66M | -13.80M | -5.48M | -3.90M | -3.69M |
| Operating Income Ratio | -1,199.10% | -1,118.40% | 0.00% | -1,378.60% | -29,636.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -845.00K | -4.57M | -273.00K | -225.00K | -440.00K | -420.00K | -226.00K | -328.00K | -163.00K | -9.00K |
| Income Before Tax | -12.84M | -15.75M | -10.30M | -14.01M | -12.59M | -13.08M | -14.03M | -5.81M | -4.07M | -3.70M |
| Income Before Tax Ratio | -1,283.60% | -1,575.40% | 0.00% | -1,401.10% | -30,709.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 89.00K | 78.00K | 38.00K | 131.00K | 178.00K | -60.00K | 61.00K | 254.00K | 176.00K | -9.00K |
| Net Income | -12.93M | -15.83M | -10.34M | -14.14M | -12.77M | -13.02M | -14.09M | -6.06M | -4.24M | -3.69M |
| Net Income Ratio | -1,292.50% | -1,583.20% | 0.00% | -1,414.20% | -31,143.90% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.10 | -1.35 | -1.08 | -1.86 | -1.86 | -1.90 | -1.90 | -1.79 | -1.39 | -1.07 |
| EPS Diluted | -1.10 | -1.35 | -1.08 | -1.86 | -1.86 | -1.90 | -1.90 | -1.79 | -1.39 | -1.07 |
| Weighted Avg Shares Out | 11.72M | 11.72M | 9.54M | 7.61M | 6.85M | 6.85M | 7.42M | 3.39M | 3.05M | 3.46M |
| Weighted Avg Shares Out (Dil) | 11.72M | 11.72M | 9.54M | 7.61M | 6.85M | 6.85M | 7.42M | 3.39M | 3.05M | 3.46M |
Source: https://incomestatements.info
Category: Stock Reports